ArticleBriefings in bioinformatics2025
BridgeSyn: a bridging fusion framework for drug combination synergy prediction.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MSCMF-DTB: a multi-scale cross-modal fusion framework for drug-target binding prediction.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Drug combination is a promising therapeutic strategy for complex diseases. However, only a small fraction of potential drug combinations exhibit true synergistic effects, making the prediction of drug synergy a critical yet challenging task. In this study, we propose BridgeSyn, a novel bridge fusion framework for drug synergy prediction. BridgeSyn leverages the knowledge from pretrained biological language models to enrich both drug compound and cell line representations. We introduce a bridging fusion mechanism that employs a set of shared latent tokens derived from global features, serving as a semantic interface to effectively fuse the representations of drug pairs and cell lines. By combining biological prior knowledge with this fusion strategy, BridgeSyn can capture complex biological interactions and achieve superior prediction results. Extensive experiments on two public datasets demonstrate that BridgeSyn consistently outperforms existing computation methods.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.